Tests ONM-501 injected into tumors, alone or with cemiplimab, in advanced cancers
Tests ONM-501 injected into tumors in adults with advanced solid tumors or lymphomas.
Key facts
- Who runs it
- OncoNano Medicine, Inc.
- Where
- Canton, Columbus, Dallas, Fairfax, Houston, Los Angeles, Pittsburgh, and Tamarac, United StatesSee the 9 sitesAlso in 1 other country, 7 sites
- Trial code
- Registry title
- A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 168 people, planned
- Started
- 13 Oct 2023
- Planned end
- 29 Aug 2026
- Type of study
- Interventional, 3 groups
- Treatments tested
- ONM-501
- Cemiplimab
- Record updated
- 24 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced solid tumors or lymphomas that cannot be removed by surgery or have come back and are getting worse, with no other standard treatment, and with at least one tumor that can be injected and measured.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Advanced, non-removable or recurrent solid tumors or lymphomas that are progressing since the last anti-cancer treatment, with no alternative standard therapy. At least one injectable and measurable lesion is needed.
- Earlier treatment
- No other standard treatment must be available. Cannot join if they had an investigational therapy within 5 half-lives of the agent or 4 weeks before the first dose, whichever is shorter.
Main reasons for not taking part
- Another active cancer in the past 2 years (some skin, bladder, cervix or breast cancers excepted)
- Major surgery within 4 weeks before the first dose
- Untreated brain metastases, or ones in the posterior fossa or involving the meninges
- Pregnant or breastfeeding at screening or baseline
- Active infection needing systemic treatment
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Ability to understand and willingness to sign written informed consent before performance of any study procedures
- Age ≥ 18 years
- Participants with solid tumors or lymphomas, confirmed by available histopathology records or current biopsy, that are advanced, nonresectable, or recurrent and progressing since last antitumor therapy, and for which no alternative standard therapy exists
- Participants must have a minimum of one injectable and measurable lesion
- Participants with prior Hepatitis B or C are eligible if they have adequate liver function
- Participants with human immunodeficiency virus (HIV) are eligible if on established HAART for a minimum of 4 weeks prior to enrollment, have an HIV viral load <400 copies/mL, and have CD4+ T-cell (CD4+) counts ≥ 350 cells/uL
- Adequate bone marrow function:
- Adequate liver function
Who cannot take part
- Other malignancy active within the previous 2 years except for basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast that has completed curative therapy
- Major surgery within 4 weeks before the first dose of study drug
- Brain metastases that are untreated or in the posterior fossa or involve the meninges. Participants with stable or previously treated progressing brain metastases (except in the posterior fossa or involving the meninges) may be permitted in a case-by-case basis at the Sponsor's discretion
- Has uncontrolled or poorly controlled hypertension as defined by a sustained BP > 9. Has received prior investigational therapy within 5 half-lives of the agent or 4 weeks before the first administration of study drug, whichever is shorter
- Has had any major cardiovascular event within 6 months prior to study drug 10. Has known hypersensitivity to any component in the formulation of ONM-501
- Has a condition requiring systemic treatment with corticosteroids
- Has an active infection requiring systemic treatment
- Has known hypersensitivity to any component in the formulation of cemiplimab
- Has any active or recent history of a known or suspected autoimmune disease or recent history of a syndrome that required systemic corticosteroids (>10 mg daily prednisone equivalent)
- Prolongation of corrected QT (QTc) interval to >470 millisecond (ms) for males and females when electrolytes balance is normal
- Females who are breastfeeding or pregnant at screening or baseline
- Females of childbearing potential that refuse to use a highly effective method of contraception
- Is participating in another therapeutic clinical trial; Additional Exclusion Criteria for ONM-501 in Combination with cemiplimab (Part 1b)
Where in United States
Also in 1 other country, 7 sites
- Gabrail Cancer Center ResearchCanton, United StatesNo longer taking part
- Ohio State UniversityColumbus, United StatesNo longer taking part
- University of Texas Southwestern Medical CenterDallas, United StatesNo longer taking part
- Virginia Cancer Specialists PCFairfax, United StatesNo longer taking part
- MD Anderson Cancer CenterHouston, United StatesNo longer taking part
- California Research InstituteLos Angeles, United StatesNo longer taking part
- Allegheny Health NetworkPittsburgh, United StatesNo longer taking part
- UPMC Hillman Cancer CenterPittsburgh, United StatesNo longer taking part
- BRCR GlobalTamarac, United StatesNo longer taking part
About the trial
What the trial wants to find out
A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibitor in patients with advanced solid tumors and lymphomas.
The 3 groups in the trial
- Part 1a: Monotherapy Dose EscalationTreatment being tested
ONM-501 will be administered as intratumoral injections once per week for three weeks, followed by three weeks without ONM-501 administration. Each dosing cycle will be 21 days.
Treatment: ONM-501
- Part 1b: ONM-501 in Combination with cemiplimabTreatment being tested
ONM-501 will be administered as intratumoral injections once per week for three weeks followed by three weeks without ONM-501 administration. Each dosing cycle will be 21 days. The combination agent will be administered according to standard protocol, once every three weeks.
Treatment: ONM-501 and Cemiplimab
- Part 2: RDE ONM-501 in Combination with cemiplimab in indication-specific expansion cohortsTreatment being tested
Once the recommended doses for expansion (RDEs) are determined for ONM-501 + ICI combination or ONM-501 monotherapy, the expansion phase of the study will be initiated. The expansion phase will enroll patients in one to three indication-specific expansion cohorts.
Treatment: ONM-501 and Cemiplimab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas
- Plain-language title
- Tests ONM-501 injected into tumors, alone or with cemiplimab, in advanced cancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 24 December 2025